Minos Biosciences incorporated
Spin-off from ESPCI Paris
Our approach
Minos Biosciences BRIDGES MOLECULAR and CELL BIOLOGY in a manner never achieved before, allowing scientists to uncover the full picture of cell diversity and dynamics.
SINGLE-CELL REVOLUTION
Single-cell analysis is key to tackle cell diversity, and it has become in recent years an irreplaceable tool in all fields of biological and medical research.
Current single-cell technologies however, despite their remarkable progress, address only fragments of the puzzle – whereas combining multiple modes of single-cell analysis is essential to unlock the complexity of biology and reveal the complete picture.
MINOS SOLUTION
By combining MULTI-OMICS ANALYSIS with FUNCTIONAL ASSAYS at cell resolution and at high throughput, Minos’ solution provides a new paradigm in single-cell analysis that will open up new frontiers in life science research, precision medicine and diagnostics.
This is enabled using a breakthrough microfluidics concept to isolate cells combined with innovative approaches in imaging, molecular biology and also bioinformatics.
It will provide highly accurate insights into complex cell populations and their dynamics, opening up unique perspectives in a vast array of fundamental and translational research areas, as well as precision medicine – therapeutics and diagnostics.
MINOS IMPACT
Minos solution has the potential to tremendously impact major healthcare fields, such as:
- Cancer disease: connecting genetic & non-genetic factors, plasticity and cell environment will be essential to understand tumour evolution and drug resistance, to design better and more personalized therapeutic strategies.
- Autoimmune disorders: unravelling the complex role of immune cells at the multi-omic and phenotypic levels will result in the development of better treatments.
- Infectious disease: correlating host-pathogen interaction to genetic and epigenetic variations will allow elucidation infection and proliferation mechanisms to improve therapy and prevention.
Our History
Founded in January 2020 and incubated at the Institut Pierre-Gilles de Gennes in Paris (PC’up), Minos Biosciences emerged from several years of research and development in the interdisciplinary and highly innovative environment that characterize the ESPCI Paris – PSL engineering school and the research campus of Université PSL in Paris.
In early April 2021, Minos Biosciences closed a €1.5M financing round led by Elaia Partners via the PSL Innovation Fund.
In October 2021 and January 2022, Minos obtained an aggregated 1.7 M€ in public funding from BPI France, through the French Tech Seed and ADD (« Aide au développement deeptech ») programmes.
Meet Our Team
Luc SELIG,
PhD
CEO of CYTOO, Independent Board member
Anne-Sophie Carrese
Elaia Partners, President of the Board
Andrew Griffiths,
PhD
Co-founder, Professor at ESPCI Paris – PSL
Patrick Tabeling,
PhD
Co-founder, Professor at ESPCI Paris – PSL
Fergus McKenzie,
PhD, HDR
Chief Executive Officer
Pierre Le Ber,
PhD
Chief Operating Officer
Hubert Geisler,
PhD
Head of microfluidics,
co-founder
Gaël Blivet-Bailly,
PhD
Head of biology,
co-founder
Mathieu Bahin
–
Head of bioinformatics
Aurélien de Reyniès, PhD
University professor & hospital practitioner (PUPH) at Paris University and Aphorisme
Jérôme Cros, MD-PhD
Professor of pathology & hospital practitioner (PUPH) at Paris University
Andrew Griffiths, PhD
Biochemistry, Professor at ESPCI Paris – PSL
Yannick Rondelez, PhD
Molecular systems, Director of Research CNRS at ESPCI Paris – PSL
Patrick Tabeling, PhD
Microfluidics, Professor at ESPCI Paris – PSL
Our Partners
Explore our open positions on Linkedin ➞
Contact us
By email at
contact@minos.bio